The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?

Yuqing Ye, Ying Ma, Jesse Zhu

Research output: Journal PublicationArticlepeer-review

33 Citations (Scopus)


Dry powder inhalation therapy has been shown to be an effective method for treating respiratory diseases like asthma, Chronic Obstructive Pulmonary Diseases and Cystic Fibrosis. It has also been widely accepted and used in clinical practices. Such success has led to great interest in inhaled therapy on treating systemic diseases in the past two decades. The current coronavirus (COVID-19) pandemic also has increased such interest and is triggering more potential applications of dry powder inhalation therapy in vaccines and antivirus drugs. Would the inhaled dry powder therapy on systemic disorders be as encouraging as expected? This paper reviews the marketed and in-development dry powder inhaler (DPI) products on the treatment of systemic diseases, their status in clinical trials, as well as the potential for COVID-19 treatment. The advancements and unmet problems on DPI systems are also summarized. With countless attempts behind and more challenges ahead, it is believed that the dry powder inhaled therapy for the treatment of systemic disorders still holds great potential and promise.

Original languageEnglish
Article number121457
JournalInternational Journal of Pharmaceutics
Publication statusPublished - 25 Feb 2022
Externally publishedYes


  • COVID-19
  • Dry powder inhalation
  • Local lung diseases
  • Pulmonary drug delivery
  • Systemic disorders

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?'. Together they form a unique fingerprint.

Cite this